Medifron DBT Co. Ltd. said its first-quarter normalized net income amounted to a loss of 4.05 South Korean won per share, compared with a loss of 22 chon per share in the prior-year period.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was a loss of 99.9 million won, compared with a loss of 5.5 million won in the prior-year period.
The normalized profit margin dropped to negative 4.3% from negative 0.3% in the year-earlier period.
Total revenue grew 41.7% year over year to 2.30 billion won from 1.63 billion won, and total operating expenses increased 42.7% year over year to 2.33 billion won from 1.63 billion won.
Reported net income came to a loss of 159.9 million won, or a loss of 6.48 won per share, compared to a loss of 8.8 million won, or a loss of 35 chon per share, in the year-earlier period.
As of May 13, US$1 was equivalent to 1,177.12 South Korean won.
